![](https://investorshub.advfn.com/uicon/41873.png?cb=1581979840)
Thursday, January 16, 2020 2:14:56 PM
Status Action Quantity
Symbol Type Price
Act. Price
Time-in-Force Reported
Filled Buy 50 NK Limit 7.85 -- -- 12:57:28 01/16/20
Filled Buy 500 NK Limit 7.91 -- -- 12:12:00 01/16/20
Filled Buy 2200 NK Limit 7.8999 -- -- 12:11:07 01/16/20
Filled Sell 2900 SDC Limit 13.2001 -- -- 12:10:32 01/16/20
Filled Buy 300 SDC Limit 13.1799 -- -- 11:55:55 01/16/20
Filled Sell 300 NK Limit 8.0294 -- -- 11:55:01 01/16/20
Filled Buy 100 SDC Limit 13.2299 -- -- 11:48:47 01/16/20
Filled Buy 150 SDC Limit 13.43 -- -- 11:38:03 01/16/20
Filled Buy 2285 SDC Limit 13.43 -- -- 11:38:03 01/16/20
Filled Buy 65 SDC Limit 13.43 -- -- 11:38:03 01/16/20
Filled Sell 200 NK Limit 9.45 -- -- 11:25:56 01/16/20
Filled Sell 600 NK Limit 9.20 -- -- 11:08:52 01/16/20
Filled Sell 1325 NK Limit 9.20 -- -- 11:08:53 01/16/20
Filled Buy 400 NK Limit 8.75 -- -- 10:57:32 01/16/20
Filled Buy 100 NK Limit 5.99 -- -- 10:17:54 01/16/20
Filled Buy 100 NK Limit 5.99 -- -- 10:17:54 01/16/20
Filled Buy 50 NK Limit 5.99 -- -- 10:17:54 01/16/20
Filled Buy 100 NK Limit 5.99 -- -- 10:17:54 01/16/20
Recent IBRX News
- ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors • Business Wire • 06/20/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:50:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:49:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:49:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:49:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:49:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:49:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:36:10 PM
- ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update • Business Wire • 06/07/2024 01:13:00 PM
- Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast • Business Wire • 05/17/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 09:00:00 PM
- ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA® • Business Wire • 05/07/2024 12:00:00 PM
- ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types • Business Wire • 05/02/2024 08:04:00 PM
- ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association • Business Wire • 04/30/2024 12:00:00 PM
- ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer • Business Wire • 04/25/2024 04:03:00 AM
- ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer • Business Wire • 04/23/2024 01:56:00 AM
- NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy • Business Wire • 03/06/2024 02:00:00 PM
- N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study • Business Wire • 03/05/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:43:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:40:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:38:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2024 02:28:02 AM
- ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial • Business Wire • 02/21/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 02:14:34 AM
- ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG • Business Wire • 02/05/2024 02:00:00 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM